Cannabis Firms Set to Explode
Published: Dec 31, 2018 12:02 p.m. ET
December 31, 2018 (ACCESSWIRE via COMTEX) -- HENDERSON, NV / ACCESSWIRE / December 31, 2018 / The market is rallying, and cannabis stocks are ready to rally as well. The companies below could lead the charge heading into 2019.
An extremely interesting company that we have discovered is OWCP (OWC Pharmaceuticals Research Corp.). If this is your first time hearing about OWCP, start doing your own research immediately. OWCP is a cannabinoid-based pharmaceutical firm, that is conducting impressive research. OWCP has been at the forefront of cannabinoid research for years and is flying under the radar. When the public at large, as well as the street, find out about OWCP things could become very interesting.
Today, we are highlighting: OWC Pharmaceutical Research Corp. (OWCP), GW Pharmaceuticals plc (NASDAQ: GWPH), INSYS Therapeutics, Inc. (NASDAQ: INSY), Aphria, Inc. (NYSE: APHA), and Tilray, Inc. (TLRY).
The people condemning legal marijuana as the next Big Tobacco seem silly. After all, cigarettes kill 7 million people each year, according to the World Health Organization, while the cannabis death toll remains at zero.
That's why we like the product that OWC Pharmaceutical Research Corp. (OWCP) (market cap:$15.59M Share Price) is developing. OWCP, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, has successfully produced its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as a smoking substitute. OWCP will now be able to begin its clinical testing program for this dosing form. OWCP has received an IRB approval to conduct a pharmaco-kinetic (PK) safety study of its sublingual tablet.
OWCP is also developing a cannabis-based topical ointment that is close to completing its first ever safety study, conducted at Sheba Medical Center, Tel Hashomer, Israel.
OWCP's multiple products make them desirable to a wider variety of larger companies, at this stage the company is worth taking a serious look at.
GW Pharmaceuticals plc GWPH, +2.09%
Market Cap: $3.144B, current share price: $97.33
GWPH is currently focusing on Epidiolex's US commercial launch. The stock price is down considerably from just a few months ago, and has lots of room to grow in our opinion.
A biotech researching potential CBD treatments, INSYS Therapeutics, Inc. (INSY) (market cap:$395.11M Share Price) announced results from its latest study at the American Epilepsy Society 2018 annual meeting. INSY found their pharmaceutical-grade cannabidiol (CBD) oral solution was generally well-tolerated-even at high doses-as an investigational treatment for refractory pediatric epilepsy. This is promising news for the company.
Aphria, Inc. (APHA) (market cap:$1.44B)(share price:$5.82), announced recently that the Company had completed its second shipment of approximately 20 kg of medical cannabis to its Australian-based partner Althea Company Pty Ltd.
Tilray, Inc. (TLRY) (market cap:$6.66B)(share price:$71.50) partnering up with AB InBev, one of the world's leading beverage producers, to research non-alcohol beverages containing tetrahydrocannabinol (THC) and cannabidiol (CBD). The partnership is limited to Canada and decisions regarding the commercialization of the beverages will be made in the future.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (''Regal Consulting''
. Regal Consulting has agreed to a one-month term consulting agreement with OWCP dated 12/25/18. All payments were made directly by OWCP Pharmaceuticals Research Corp. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. OWCP was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC
Published: Dec 31, 2018 12:02 p.m. ET
December 31, 2018 (ACCESSWIRE via COMTEX) -- HENDERSON, NV / ACCESSWIRE / December 31, 2018 / The market is rallying, and cannabis stocks are ready to rally as well. The companies below could lead the charge heading into 2019.
An extremely interesting company that we have discovered is OWCP (OWC Pharmaceuticals Research Corp.). If this is your first time hearing about OWCP, start doing your own research immediately. OWCP is a cannabinoid-based pharmaceutical firm, that is conducting impressive research. OWCP has been at the forefront of cannabinoid research for years and is flying under the radar. When the public at large, as well as the street, find out about OWCP things could become very interesting.
Today, we are highlighting: OWC Pharmaceutical Research Corp. (OWCP), GW Pharmaceuticals plc (NASDAQ: GWPH), INSYS Therapeutics, Inc. (NASDAQ: INSY), Aphria, Inc. (NYSE: APHA), and Tilray, Inc. (TLRY).
The people condemning legal marijuana as the next Big Tobacco seem silly. After all, cigarettes kill 7 million people each year, according to the World Health Organization, while the cannabis death toll remains at zero.
That's why we like the product that OWC Pharmaceutical Research Corp. (OWCP) (market cap:$15.59M Share Price) is developing. OWCP, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, has successfully produced its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as a smoking substitute. OWCP will now be able to begin its clinical testing program for this dosing form. OWCP has received an IRB approval to conduct a pharmaco-kinetic (PK) safety study of its sublingual tablet.
OWCP is also developing a cannabis-based topical ointment that is close to completing its first ever safety study, conducted at Sheba Medical Center, Tel Hashomer, Israel.
OWCP's multiple products make them desirable to a wider variety of larger companies, at this stage the company is worth taking a serious look at.
GW Pharmaceuticals plc GWPH, +2.09%
Market Cap: $3.144B, current share price: $97.33
GWPH is currently focusing on Epidiolex's US commercial launch. The stock price is down considerably from just a few months ago, and has lots of room to grow in our opinion.
A biotech researching potential CBD treatments, INSYS Therapeutics, Inc. (INSY) (market cap:$395.11M Share Price) announced results from its latest study at the American Epilepsy Society 2018 annual meeting. INSY found their pharmaceutical-grade cannabidiol (CBD) oral solution was generally well-tolerated-even at high doses-as an investigational treatment for refractory pediatric epilepsy. This is promising news for the company.
Aphria, Inc. (APHA) (market cap:$1.44B)(share price:$5.82), announced recently that the Company had completed its second shipment of approximately 20 kg of medical cannabis to its Australian-based partner Althea Company Pty Ltd.
Tilray, Inc. (TLRY) (market cap:$6.66B)(share price:$71.50) partnering up with AB InBev, one of the world's leading beverage producers, to research non-alcohol beverages containing tetrahydrocannabinol (THC) and cannabidiol (CBD). The partnership is limited to Canada and decisions regarding the commercialization of the beverages will be made in the future.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (''Regal Consulting''
. Regal Consulting has agreed to a one-month term consulting agreement with OWCP dated 12/25/18. All payments were made directly by OWCP Pharmaceuticals Research Corp. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. OWCP was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice. http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC
